BidaskClub cut shares of Audentes Therapeutics (NASDAQ:BOLD) from a strong-buy rating to a buy rating in a report issued on Thursday.
Several other equities research analysts have also weighed in on BOLD. Zacks Investment Research upgraded Audentes Therapeutics from a hold rating to a buy rating and set a $37.00 target price for the company in a report on Thursday, March 8th. HC Wainwright set a $37.00 target price on Audentes Therapeutics and gave the stock a buy rating in a report on Friday, March 9th. William Blair restated a buy rating on shares of Audentes Therapeutics in a report on Friday, March 9th. Cowen restated a buy rating on shares of Audentes Therapeutics in a report on Friday, March 9th. Finally, Wedbush restated an outperform rating and issued a $56.00 target price on shares of Audentes Therapeutics in a report on Friday, March 9th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the company’s stock. Audentes Therapeutics has an average rating of Buy and an average target price of $35.56.
Shares of Audentes Therapeutics (BOLD) traded up $0.06 during midday trading on Thursday, hitting $29.51. The company had a trading volume of 118,296 shares, compared to its average volume of 444,029. Audentes Therapeutics has a 1-year low of $13.90 and a 1-year high of $41.80.
Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.82) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.91) by $0.09. research analysts expect that Audentes Therapeutics will post -3.46 earnings per share for the current year.
In other news, Director Louis G. Lange sold 18,000 shares of the company’s stock in a transaction that occurred on Friday, December 22nd. The stock was sold at an average price of $30.88, for a total transaction of $555,840.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Orbimed Advisors Llc sold 58,428 shares of the company’s stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $34.06, for a total value of $1,990,057.68. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,087,707 shares of company stock valued at $38,055,301. Corporate insiders own 47.30% of the company’s stock.
Hedge funds have recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in shares of Audentes Therapeutics during the third quarter worth approximately $143,000. Teacher Retirement System of Texas acquired a new position in shares of Audentes Therapeutics during the fourth quarter worth approximately $208,000. MetLife Investment Advisors LLC acquired a new position in shares of Audentes Therapeutics during the fourth quarter worth approximately $248,000. Nationwide Fund Advisors lifted its holdings in shares of Audentes Therapeutics by 288.9% during the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock worth $164,000 after buying an additional 6,384 shares during the last quarter. Finally, Trexquant Investment LP acquired a new position in shares of Audentes Therapeutics during the third quarter worth approximately $295,000. Institutional investors own 67.35% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Audentes Therapeutics (BOLD) Downgraded by BidaskClub to “Buy”” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/03/16/audentes-therapeutics-bold-downgraded-by-bidaskclub-to-buy.html.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.